SILK - Silk Road Medical Inc Stock Price, Fair Value and News

22.18USD-0.27 (-1.20%)Market Closed

Market Summary

USD22.18-0.27

Market Closed

-1.20%

SILK Alerts

Losses in recent quarter

SILK Stock Price

View Fullscreen

SILK RSI Chart

SILK Valuation

Market Cap

874.9M

Price/Earnings (Trailing)

-16.38

Price/Sales (Trailing)

4.72

Price/Free Cashflow

-23.78

SILK Price/Sales (Trailing)

SILK Profitability

Return on Equity

-36.27%

Return on Assets

-21.17%

Free Cashflow Yield

-4.21%

SILK Fundamentals

SILK Revenue

Revenue (TTM)

185.5M

Rev. Growth (Yr)

20.81%

Rev. Growth (Qtr)

2.57%

SILK Earnings

Earnings (TTM)

-53.4M

Earnings Growth (Yr)

14.12%

Earnings Growth (Qtr)

-8.65%

Breaking Down SILK Revenue

Last 7 days

10.0%

Last 30 days

26.7%

Last 90 days

23.0%

Trailing 12 Months

-31.3%

How does SILK drawdown profile look like?

SILK Financial Health

Current Ratio

11.05

Debt/Equity

0.52

Debt/Cashflow

-0.46

SILK Investor Care

Shares Dilution (1Y)

1.85%

Diluted EPS (TTM)

-1.38

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	185.5M	0	0	0
2023	150.7M	162.9M	169.9M	177.1M
2022	107.4M	114.2M	126.8M	138.6M
2021	78.3M	89.7M	94.3M	101.5M
2020	69.5M	69.7M	72.7M	75.2M
2019	41.6M	48.8M	56.2M	63.4M
2018	19.3M	24.4M	29.5M	34.6M
2017	0	0	0	14.3M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Silk Road Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 05, 2024	klemz kevin m	sold	-42,871	17.169	-2,497	evp/chief legal officer/sec.
Mar 05, 2024	ruedy richard	sold	-65,242	17.169	-3,800	evpclin&reg.affairs&qa
Mar 05, 2024	buchanan lucas w.	sold	-169,578	17.169	-9,877	coo/cfo
Mar 05, 2024	ballinger kevin j.	bought	198,783	16.99	11,700	-
Mar 05, 2024	davis andrew s.	sold	-94,103	17.169	-5,481	chief commercial officer
Mar 05, 2024	jones marie l.	sold	-44,673	17.169	-2,602	vp, finance and cao
Mar 01, 2024	klemz kevin m	acquired	-	-	42,818	evp/chief legal officer/sec.
Mar 01, 2024	mckhann chas	acquired	-	-	110,313	chief executive officer
Mar 01, 2024	davis andrew s.	acquired	-	-	62,201	chief commercial officer
Mar 01, 2024	buchanan lucas w.	acquired	-	-	74,954	coo/cfo

Which funds bought or sold SILK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.91	-6,820	70,788	-%
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-3,018,060	-	-%
May 16, 2024	COMERICA BANK	unchanged	-	260	788	-%
May 15, 2024	Engineers Gate Manager LP	reduced	-92.88	-2,158,500	256,663	0.01%
May 15, 2024	BARCLAYS PLC	reduced	-28.93	39,000	686,000	-%
May 15, 2024	Squarepoint Ops LLC	added	270	799,715	975,998	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	514	1,557	-%
May 15, 2024	QUADRANT CAPITAL GROUP LLC	unchanged	-	3,140	9,509	-%
May 15, 2024	Parkman Healthcare Partners LLC	added	55.69	8,861,760	15,551,800	1.91%
May 15, 2024	Voya Investment Management LLC	reduced	-18.75	40,442	230,136	-%

Are Funds Buying or Selling SILK?

Are funds buying SILK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SILK

No. of Funds

SILK Alerts

Losses in recent quarter

Unveiling Silk Road Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	7.43%	2,891,769	SC 13G/A
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G/A
Feb 05, 2024	goldman sachs group inc	5.8%	2,277,063	SC 13G
Jan 26, 2024	blackrock inc.	7.7%	3,012,320	SC 13G/A
Oct 20, 2023	flynn james e	0.00%	0	SC 13G
Aug 10, 2023	alliancebernstein l.p.	0.1%	46,800	SC 13G/A
May 10, 2023	wasatch advisors lp	-	0	SC 13G/A
Feb 14, 2023	alliancebernstein l.p.	6.9%	2,616,795	SC 13G/A
Feb 13, 2023	capital world investors	7.8%	2,966,730	SC 13G/A
Feb 10, 2023	flynn james e	3.66%	1,396,640	SC 13G/A

Recent SEC filings of Silk Road Medical Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
Apr 30, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Mar 07, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Silk Road Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-3.99%	-3.65%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	2.45%	-5.81%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-10.40%	-6.17%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-11.17%	-17.84%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.44%	23.99%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	4.37%	-2.87%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	0.92%	-22.34%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-7.86%	-29.32%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.46%	29.28%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.82%	-4.37%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	2.50%	-12.21%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-	-1.96%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-1.38%	-32.77%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	10.79%	-74.07%	-2.46	1.11	14.25%	-10.06%
AEMD	1.1M	3.7M	-72.22%	29.03%	-0.09	0.29	5.77%	8.23%

Silk Road Medical Inc News

Latest updates

Silk Road Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	2.6%	48,484,000	47,270,000	44,435,000	45,298,000	40,131,000	40,070,500	37,374,000	33,173,000	28,021,000	28,265,000	24,701,000	26,456,000	22,053,000	21,133,000	20,067,000	15,094,000	18,933,000	18,634,000	17,026,000	14,928,000	12,766,000
Gross Profit	4.9%	36,501,000	34,802,000	32,385,000	32,294,000	27,605,000	29,091,500	28,066,000	24,161,000	19,444,000	21,031,500	18,625,000	19,858,000	16,515,000	15,916,000	14,579,000	9,758,000	13,683,000	13,913,000	12,856,000	11,231,000	9,427,000
Operating Expenses	4.6%	51,435,000	49,175,000	46,056,000	46,610,000	44,515,000	41,721,500	37,292,000	38,355,000	35,398,000	35,093,500	31,916,000	29,810,000	26,678,000	30,909,500	23,913,000	19,151,000	22,823,000	21,420,000	20,251,000	17,248,000	16,573,000
S&GA Expenses	4.3%	40,775,000	39,111,000	36,009,000	35,830,000	34,082,000	32,521,500	28,821,000	27,700,000	27,275,000	27,595,000	25,049,000	22,549,000	21,194,000	20,872,000	19,202,000	15,758,000	19,692,000	18,155,500	17,064,000	14,135,000	13,866,000
R&D Expenses	5.9%	10,660,000	10,064,000	10,047,000	10,780,000	10,433,000	9,200,000	8,471,000	10,655,000	8,123,000	7,498,500	6,867,000	7,261,000	5,484,000	10,037,500	4,711,000	3,393,000	3,131,000	3,264,500	3,187,000	3,113,000	2,707,000
EBITDA Margin	-	-	-	-	-	-	-	-	-0.41	-0.44	-0.47	-	-	-0.55	-0.56	-0.64	-0.67	-0.67	-0.74	-0.57	-0.66	-0.78
Interest Expenses	-0.7%	1,721,000	1,734,000	1,732,000	1,712,000	1,693,000	1,732,000	1,714,000	1,031,000	621,000	634,000	633,000	628,000	623,000	791,000	1,215,000	1,203,000	1,202,000	1,216,500	1,176,000	1,207,000	1,352,000
EBT Margin	-	-	-	-	-	-	-	-	-0.44	-0.46	-0.49	-	-	-0.60	-0.63	-0.72	-0.75	-0.75	-0.83	-0.67	-0.77	-0.90
Net Income	-8.6%	-14,136,000	-13,011,000	-12,788,000	-13,484,000	-16,460,000	-12,614,000	-10,319,000	-15,398,000	-16,679,000	-14,693,000	-13,885,000	-10,539,000	-10,694,000	-16,756,000	-10,315,000	-10,353,000	-9,941,000	-8,291,000	-8,007,000	-11,959,000	-24,158,000
Net Income Margin	8.5%	-0.29	-0.31	-0.33	-0.32	-0.36	-0.40	-0.45	-0.53	-0.52	-0.49	-0.55	-0.54	-	-	-	-	-	-	-	-	-
Free Cashflow	-76.4%	-15,710,000	-8,906,000	-7,131,000	-5,050,000	-12,434,000	-4,291,000	-5,115,000	-11,383,000	-16,797,000	-14,184,000	-7,627,000	-9,843,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-4.9%	252	265	261	263	260	270	163	163	143	157	166	168	170	179	184	188	127	137	139	143	39.00
Current Assets	-2.1%	236	241	241	233	230	255	147	147	128	143	154	159	164	173	178	181	120	112	132	136	29.00
Cash Equivalents	12.0%	23.00	20.00	29.00	28.00	50.00	55.00	51.00	88.00	94.00	110	106	102	95.00	70.00	63.00	74.00	28.00	39.00	113	119	16.00
Inventory	2.0%	30.00	30.00	22.00	19.00	17.00	19.00	20.00	18.00	18.00	18.00	16.00	13.00	12.00	10.00	11.00	12.00	12.00	10.00	9.00	9.00	8.00
Net PPE	-0.4%	8.00	8.00	8.00	9.00	9.00	9.00	10.00	10.00	10.00	8.00	5.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
Liabilities	-8.0%	105	114	108	108	102	106	105	103	75.00	77.00	77.00	72.00	69.00	72.00	64.00	60.00	63.00	66.00	61.00	58.00	91.00
Current Liabilities	-29.5%	21.00	30.00	24.00	24.00	21.00	24.00	24.00	21.00	29.00	26.00	21.00	17.00	16.00	20.00	15.00	12.00	14.00	17.00	12.00	9.00	11.00
Short Term Borrowings	-	-	-	-	-	-	-	-	-	10.00	4.00	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	0.3%	76.00	76.00	75.00	75.00	75.00	75.00	74.00	74.00	39.00	45.00	49.00	49.00	49.00	49.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00
LT Debt, Non Current	-100.0%	-	76.00	75.00	75.00	75.00	75.00	74.00	74.00	39.00	45.00	49.00	49.00	49.00	49.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00
Shareholder's Equity	-2.6%	147	151	153	156	158	164	57.00	60.00	68.00	79.00	88.00	96.00	101	108	120	127	64.00	72.00	77.00	84.00	-
Retained Earnings	-3.5%	-413	-399	-386	-373	-360	-343	-331	-320	-305	-288	-274	-260	-249	-238	-222	-211	-201	-191	-183	-175	-163
Additional Paid-In Capital	1.9%	561	550	540	529	518	508	388	381	373	368	362	356	351	346	342	339	265	263	261	260	5.00
Shares Outstanding	0.7%	39.00	39.00	39.00	39.00	39.00	38.00	35.00	35.00	35.00	35.00	35.00	34.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,200	-	-	-	1,300	-	-	-	1,600	-	-	-	1,400	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-81.3%	-15,322	-8,453	-6,798	-4,616	-12,147	-2,724	-4,726	-10,406	-14,725	-11,432	-6,495	-9,036	-11,972	-14,269	-4,423	-11,581	-11,795	-5,261	-6,346	-9,383	-8,620
Share Based Compensation	7.8%	10,359	9,609	10,247	10,199	8,838	7,545	6,339	6,161	4,978	3,984	3,686	3,409	3,533	2,273	2,006	1,654	1,293	954	924	837	262
Cashflow From Investing	1222.8%	17,741	-1,580	7,456	-19,158	6,106	-104,951	-32,895	-22,150	-2,072	14,250	7,968	14,193	36,233	12,898	-7,386	-14,797	-108	-69,619	-131	-89.00	-117
Cashflow From Financing	-100.0%	-	1,055	130	1,592	1,110	111,727	1,213	26,591	168	1,771	2,242	2,117	848	8,369	835	72,268	274	1,784	507	112,210	-744

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SILK Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Condensed Statements of Operations and Comprehensive Loss [Abstract]
Revenue	$ 48,484	$ 40,131
Cost of goods sold	11,983	12,526
Gross profit	36,501	27,605
Operating expenses:
Research and development	10,660	10,433
Selling, general and administrative	40,775	34,082
Total operating expenses	51,435	44,515
Loss from operations	(14,934)	(16,910)
Interest income	2,471	2,287
Interest expense	(1,721)	(1,693)
Other income (expense), net	48	(144)
Net loss	(14,136)	(16,460)
Other comprehensive income (loss):
Unrealized gain (loss) on investments, net	(89)	249
Other comprehensive income (loss)	(89)	249
Comprehensive loss	$ (14,225)	$ (16,211)
Net loss per share, basic	$ (0.36)	$ (0.43)
Net loss per share, diluted	$ (0.36)	$ (0.43)
Weighted average common shares used to compute net loss per share, basic	39,261,496	38,532,202
Weighted average common shares used to compute net loss per share, diluted	39,261,496	38,532,202

SILK Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 22,629	$ 20,210
Short-term investments	151,833	161,264
Accounts receivable, net	27,203	23,573
Inventories	30,486	29,876
Prepaid expenses and other current assets	3,543	5,912
Total current assets	235,694	240,835
Long-term investments	2,027	9,456
Property and equipment, net	8,085	8,114
Other non-current assets	6,508	6,904
Total assets	252,314	265,309
Current liabilities:
Accounts payable	2,966	5,676
Accrued liabilities	18,371	24,607
Total current liabilities	21,337	30,283
Long-term debt	75,886	75,626
Other liabilities	7,806	8,249
Total liabilities	105,029	114,158
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.001 par value Shares authorized: 5,000,000 at March 31, 2024 and December 31, 2023 Shares issued and outstanding: none at March 31, 2024 and December 31, 2023
Common stock, $0.001 par value Shares authorized: 100,000,000 at March 31, 2024 and December 31, 2023 Shares issued and outstanding: 39,436,634 and 39,165,481 at March 31, 2024 and December 31, 2023, respectively	39	39
Additional paid-in capital	560,854	550,495
Accumulated other comprehensive income (loss)	(17)	72
Accumulated deficit	(413,591)	(399,455)
Total stockholders’ equity	147,285	151,151
Total liabilities and stockholders’ equity	$ 252,314	$ 265,309

About Silk Road Medical Inc

Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a specialty balloon for the TCAR procedure. Silk Road Medical, Inc. was incorporated in 2007 and is headquartered in Sunnyvale, California.

CEO	Ms. Erica J. Rogers
WEBSITE	https://silkroadmed.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	414

Silk Road Medical Inc Frequently Asked Questions

What is the ticker symbol for Silk Road Medical Inc? What does SILK stand for in stocks?

SILK is the stock ticker symbol of Silk Road Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Silk Road Medical Inc (SILK)?

As of Thu May 16 2024, market cap of Silk Road Medical Inc is 885.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SILK stock?

You can check SILK's fair value in chart for subscribers.

What is the fair value of SILK stock?

You can check SILK's fair value in chart for subscribers. The fair value of Silk Road Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Silk Road Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SILK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Silk Road Medical Inc a good stock to buy?

The fair value guage provides a quick view whether SILK is over valued or under valued. Whether Silk Road Medical Inc is cheap or expensive depends on the assumptions which impact Silk Road Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SILK.

What is Silk Road Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, SILK's PE ratio (Price to Earnings) is -16.58 and Price to Sales (PS) ratio is 4.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SILK PE ratio will change depending on the future growth rate expectations of investors.